Jump to content
  • Sign Up

GW Pharmaceuticals expects approval for MS drug derived from cannabis


Recommended Posts

ello all :bongon:

 

just saw this

 

GW Pharmaceuticals, which makes drugs derived from cannabis, is due to have its first medicine on the market within months.

 

The British biotech company announced that regulators in the UK and Spain said that there were no quality, safety or efficacy issues with Sativex, its drug to treat spasticity in multiple sclerosis (MS).

 

Full approval is expected within three months. Sativex has been much delayed, but the news that it was finally close to approval sent GW’s shares up 15 per cent to 115p.

 

Sativex is the first prescription medication in the world to be derived directly from the cannabis plant. Marijuana plants grown at secret locations in the English countryside provide its main ingredient. It is an oral spray which works by acting on the same parts of the brain that respond to smoking cannabis. Sativex works by protecting against damage to nerve cells and restoring normal functions to nerve cells that are already damaged. Its approval will trigger a payment of £10 million to the company by Bayer, the pharmaceutical company which co-owns the drug in the UK, and £2.5 million from the Spanish partner Almirall.

 

The company is still 22 per cent owned by its founders Geoffrey Guy and Brian Whittle, who also founded Phytopharm.

 

GW will be able to expand into other European countries quickly under the mutual recognition procedure, in which countries recognise drugs that have been approved elsewhere more quickly. The company hopes that recognition will be confirmed in the first half of next year.

 

Justin Gover, managing director of GW, said: “This will also allow us to start thinking about expanding into markets beyond Europe.”

 

Trials of Sativex to treat pain in cancer patients are taking place in the US.

 

Stefan Hamill, analyst at the stockbroker Execution Noble, said: “This is a watershed moment for GW where the intangible becomes tangible. The immediate benefit will be milestone payments and product royalties from launch, but the greater significance is validation of GW’s cannabinoid focused business model.”

 

http://business.timesonline.co.uk/tol/busi...icle7067564.ece - 18 March 2010

 

edit: wasn't paying attn when i posted - was meant for international news :)

Edited by hobbez
Link to comment
Share on other sites

Unfortunately the natural plant is of far better value on its own as opposed to some frankendrug from some scientist whos wearing stale underwear and has no idea that nature just simply knows better. The cannabis plant has its own chemical make-up, typically synthetic drugs are extracts of a particular chemical from a plant or synthesized version of what the extract would be, but it is only that chemical and thus has consequences because the other chemicals in the plant all will have some particular affect or function involved with how the plant works. Not a believer in pharmaceuticals.
Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using the community in any way you agree to our Terms of Use and We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.